I actually disagree. Gerald sold me on this one thing way back in July after the Conferences. The AD pharmas were very pleased with just the univariant data at the levels of accuracy they showed then! They were accurate enough to justify using LymPro. At least that's the impression Gerald gave us. So i'm not too worried about how high the sens and spec numbers will be. I'm more focused on how many pharmas are starting to sign up.

Gerald has said AMBS has been talking with these AD pharmas for a few months in preparation for the launch. By January 14th Lympro will have been open for business for 3 weeks....time for signs of business to appear. I hope he discusses that in a convincing way on the 14th.